Quick Takeaways
- Fortress Biotech, Inc. filed SCHEDULE 13D/A for Avenue Therapeutics, Inc. Common Stock, $0.0001 Par Value (ATXI).
- Disclosed ownership: 14%.
- Date of event: 31 Dec 2024.
Fortress Biotech, Inc. - 31 Dec 2024 SCHEDULE 13D/A Report for Avenue Therapeutics, Inc. Common Stock, $0.0001 Par Value (ATXI)
- Filing Manager
- Fortress Biotech, Inc.
- Reporting Manager
- Fortress Biotech, Inc.
- Symbol
- ATXI
- Shares outstanding
- 2,137,841 shares
- Disclosed Ownership
- 295,022 shares
- Ownership
- 14%
- Form type
- SCHEDULE 13D/A
- Filing time
- 03 Jan 2025, 17:50:20 UTC
- Date of event
- 31 Dec 2024
- Next filing
- 02 Apr 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Fortress Biotech, Inc. disclosed 14% ownership in Avenue Therapeutics, Inc. Common Stock, $0.0001 Par Value (ATXI) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 03 Jan 2025, 17:50.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Fortress Biotech, Inc. | 14% | 295,022 | 295,022 | 0 | /s/ Lindsay A. Rosenwald | Lindsay A. Rosenwald, M.D. / Chairman, President and Chief Executive Officer | 0001429260 |